載入中
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
前收盤價
US$2.39
−US$0.08 · -3.24%
盤前
US$2.36
−US$0.03 · -1.26%
10月8日 上午7:52 ET
盤中時間採用ET。市場資料可能有所延遲。
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
日內區間
目前US$2.39
52週區間
目前US$2.39
盤中時間採用ET。市場資料可能有所延遲。
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
日內區間
目前US$2.39
52週區間
目前US$2.39
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4748.2萬 USD | 3.02億 USD | 1668.54萬 USD | 687.52萬 USD | 434.08萬 USD |
| 銷貨成本 | 326.25萬 USD | 1374.58萬 USD | 126.18萬 USD | 88.18萬 USD | 147.48萬 USD |
| 毛利 | 4421.95萬 USD | 2.88億 USD | 1542.37萬 USD | 599.34萬 USD | 286.61萬 USD |
| 研究與開發 | 708.61萬 USD | 191.1萬 USD | 34.2萬 USD | 22.48萬 USD | 11.96萬 USD |
| 銷售、一般及管理費用 | 3782.26萬 USD | 2.55億 USD | 2263.28萬 USD | 1020.68萬 USD | 418.79萬 USD |
| 營業費用 | 4490.87萬 USD | 2.57億 USD | 2320.38萬 USD | 1067.5萬 USD | 447.18萬 USD |
| 利息收入 | 41.38萬 USD | — | — | — | — |
| 利息支出 | — | 58.72萬 USD | 70.03萬 USD | 46.82萬 USD | 52.59萬 USD |
| 折舊和攤銷 | 38.1萬 USD | 29.32萬 USD | 22.9萬 USD | 22.25萬 USD | 28.38萬 USD |
| 營業利益 | −68.91萬 USD | 3120.06萬 USD | −777.9萬 USD | −468.15萬 USD | −160.57萬 USD |
| 淨利 | −658.09萬 USD | 3188.43萬 USD | −848.3萬 USD | −719.29萬 USD | −144.54萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2015年1月29日 | 1:400 | — | — |
股票分割 | 2013年2月1日 | 1:35 | — | — |
股票分割 | 2008年11月28日 | 1:1,000 | — | — |
已生效 2015年1月29日
1:400
已生效 2013年2月1日
1:35
已生效 2008年11月28日
1:1,000
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
